4D Pharma has announced positive interim results for its Phase I/II study of a combination therapy targeting the treatment of renal cell carcinoma. The company is investigating the combination of its lead immune-oncology single strain Live Biotherapeutic MRx0518 with Merck’s (MSD) anti-PD-1 therapy, KEYTRUDA(R) (pembrolizumab) in treating renal cell carcinoma (RCC). Specifically, the combination therapy […]
